Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> MutationFrank J. Accurso, Bonnie W. Ramsey, Richard B. Moss et al.|New England Journal of Medicine|2010Cited by 802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutationJohn P. Clancy, Michael W. Konstan, Steven M. Rowe et al.|Thorax|2011Cited by 496
CFTR modulator theratyping: Current status, gaps and future directionsJohn P. Clancy, Katherine L. Tuggle, Calvin U. Cotton et al.|Journal of Cystic Fibrosis|2018Cited by 288
Myofibroblast Differentiation and Enhanced Tgf-B Signaling in Cystic Fibrosis Lung DiseaseWilliam T. Harris, Eric J. Sorscher, David R. Kelly et al.|PLoS ONE|2013Cited by 85
Alpha-1 antitrypsin limits neutrophil extracellular trap disruption of airway epithelial barrier functionKristin Hudock, John P. Clancy|Frontiers in Immunology|2023Cited by 18